Internationally respected oncologist and experienced physician to government leaders and royalty. Senior Clinical Oncologist to St Bartholomew’s Hospital and The Hospital for Sick Children Great Ormond Street. Dr P N Plowman qualified from Cambridge University with a double first in medical sciences and natural sciences and has been a consultant oncologist at St Bartholomew’s Hospital and the Hospital for Sick Children in London for thirty years. His research work has led to the introduction of aromatase inhibitors into breast cancer management and glucocorticoids into advanced prostate cancer management, thereby making significant advantages and changes in best standard care to these two common important cancers. Dr Plowman has forwarded the practice of modern radiotherapy (for example, in children) and will shortly be part of a team introducing Linac-based proton beam radiotherapy into clinical practice.

Dr Plowman leads a team of oncologists to provide CME training via online live training sessions, webinars, masterclasses, and panel discussions.


Examples of training courses include:

  1. All aspects, A-Z, of establishing a new clinic/centre/unit.
  2. How to grow your oncology clinic and attract new patients.
  3. Updates from the American Society of Clinical Oncology meetings ( ASCO)
  4. Updates from European Society of Medical Oncology (ESMO)
  5. Updates from European CanCer Organisation (ECCO)
  6. Diagnosis, staging, full characterisation of the various cancers and, then, the options for treatment of adult (and childhood) cancer. Incudes all the common cancers – lung, breast, glioma/CNS, head-and-neck including thyroid, sarcoma, gastro-intestinal, genito-urinary, gynaecological, lymphoma/ myeloma/leukaemia and rarer cancers.
  7. Screening for cancer, with recognition of predisposing hereditary/genetic predispositions (and discussions of pre-emptive considerations), the genomics of the individual cancers themselves and the increasingly important immunotherapy.
  8. How Radiotherapy maintains an important role for local control of cancer, including the principles, physics’ considerations, protection of patients and staff, the different modalities used, and radio-isotope therapies – all the themes of important lectures.
  9. The role of radiotherapy in the multi-modality treatment for cancer will be set in context.
  10. The latest updates on evidence based Chemotherapy protocols.
  11. The latest updates on genomics / genomically targeted therapy.
  12. The latest updates on predictive testing for therapies – e.g. immunotherapy.
  13. The latest updates on radiotherapy, including cryotherapy, embolization, HIFU, nanoknife and other focal ablation therapy for oligometastatic disease.
  14. The latest updates on predictive testing for ‘Smart’/genomically targeted/immunotherapy utility (from tumour biopsies or cell-free DNA analysis by NGS)
  15. Overview of the biology of Cancer
  16. Immune Recognition, Induction of the Immune Response: CD8+ T Cells, Induction of the Immune Response: CD4+ T Cells, Immune Response of NK Cells, Immune Evasion: T Cells, Immune Evasion: Other Cells, Clinical Linkage: Tumor Immunology, Mechanisms of Checkpoint Blockade, Complications of Checkpoint Blockade and Clinical Linkage: Checkpoint Blockade Therapy in Melanoma
  17. Introduction to Chimeric Antigen Receptor (CAR) T Cells and Complications of CAR T Cell Therapy
  18. Overview and discussion of Bispecific T Cell Engagers (BiTEs)
  19. Overview and discussion of Tumor Vaccines
  20. Overview and discussion of Oncolytic Viruses
  21. Overview and discussion of Novel CAR Cells
  22. Overview and discussion of Clinical Linkage: CAR T Cell Therapy
  23. The Future of Immuno-oncology